Dynavax Technologies Corporation (DVAX)
| Market Cap | 1.05B |
| Revenue (ttm) | 118.97M |
| Net Income (ttm) | -61.75M |
| Shares Out | 112.04M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | 34.25 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 24 |
| Last Price | $9.38 |
| Previous Close | $9.25 |
| Change ($) | 0.13 |
| Change (%) | 1.41% |
| Day's Open | 9.28 |
| Day's Range | 9.24 - 9.51 |
| Day's Volume | 1,283,709 |
| 52-Week Range | 3.58 - 12.44 |
The declines appear to be caused simply by volatility that's common with small biotech stocks.
EMERYVILLE, Calif., June 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced th...
Saint- Herb lain (France ) , June 3 , 2021 –Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unm...
The company signed a key deal to market its hepatitis B vaccine in Germany.
Dynavax Technologies Corporation (NASDAQ: DVAX) has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, the Hepatitis B vaccine in Germany, ...
EMERYVILLE, Calif., May 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it...
EMERYVILLE, Calif., May 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced th...
Saint- Herb lain (France) , May 19 , 2 021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant un...
The company announced the pricing of its senior convertible notes offering.
EMERYVILLE, Calif., May 11, 2021 /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced the pricing of $200.0 million aggregate principal amount of 2.50% convertible...
The biotech announced a senior convertible notes offering.
EMERYVILLE, Calif., May 10, 2021 /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced that it intends to offer, subject to market conditions and other factors, $20...
The company's hepatitis B vaccine wasn't its key growth driver.
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 37.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
EMERYVILLE, Calif., May 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported fina...
EMERYVILLE, Calif., May 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 148,500 shares o...
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMERYVILLE, Calif., April 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced ...
EMERYVILLE, Calif., April 22, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report firs...
EMERYVILLE, Calif., April 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announce...
Saint- Herb lain (France) , April 21 , 2 021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant ...
Saint- Herb lain (France) , April 20 , 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant u...
EMERYVILLE, Calif., April 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced ...
Investors cheered good news from the company's COVID-19 vaccine partner.
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
Dynavax Technologies Corporation (NASDAQ: DVAX) has announced that Valneva SE reported initial results from Part A of the Phase 1/2 trial evaluating Valneva's COVID-19 vaccine candidate, VLA2001, using ...
EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced t...
EMERYVILLE, Calif., April 2, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 142,000 shares...
CHENGDU, China and EMERYVILLE, Calif., March 24, 2021 /PRNewswire/ -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company developing transformative biologics such as vaccin...
Clover Biopharmaceuticals and Dynavax Technologies Corporation (NASDAQ: DVAX) have dosed the first participants in the SPECTRA trial of Clover's COVID-19 vaccine candidate adjuvanted with Dynavax's CpG ...
EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ry...
EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that in connection with the commencement of Ms. MacDonald's employment with the Company a...
The biotech's better-than-expected Q4 update pointed to even better days ahead.
The company's collaborations and CpG 1018 vaccine adjuvant are playing an increasingly important role.
EMERYVILLE, Calif., Feb. 25, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported fi...
Is (DVAX) Outperforming Other Medical Stocks This Year?
The company's hepatitis B virus vaccine won European Union approval.
EMERYVILLE, Calif., Feb. 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced t...
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax Technologies (DVAX) closed the most recent trading day at $9.82, moving +0.41% from the previous trading session.
EMERYVILLE, Calif., Feb. 16, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ry...
Dynavax Technologies (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
EMERYVILLE, Calif., Feb. 8, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Don...
EMERYVILLE, Calif., Feb. 3, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 7,500 shares of...
Dynavax Technologies Corporation (NASDAQ: DVAX) and Serum Institute of India (SII) have dosed the first patient in Phase 1 clinical trial evaluating tetanus, diphtheria, and acellular pertussis (Tdap) b...
The biotech had lots of good news.
Dynavax Technologies Corporation (NASDAQ: DVAX) shares are advancing solidly after the company and Clover Biopharma issued an update on their joint coronavirus vaccine program. What Happened: China-base...
About DVAX
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.... [Read more...]
| Industry Biotechnology | IPO Date Feb 19, 2004 |
| CEO Ryan Spencer | Employees 245 |
| Stock Exchange NASDAQ | Ticker Symbol DVAX |
Financial Performance
In 2020, DVAX's revenue was $46.55 million, an increase of 32.18% compared to the previous year's $35.22 million. Losses were -$75.24 million, -50.69% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for DVAX stock is "Strong Buy." The 12-month stock price forecast is 18.67, which is an increase of 99.04% from the latest price.